82
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Defining order and timing of mutations during cancer progression: the TO-DAG probabilistic graphical model

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Somatic mutations arise and accumulate both during tumor genesis and progression. However, the order in which mutations occur is an open question and the inference of the temporal ordering at the gene level could potentially impact on patient treatment. Thus, exploiting recent observations suggesting that the occurrence of mutations is a non-memoryless process, we developed a computational approach to infer timed oncogenetic directed acyclic graphs (TO-DAGs) from human tumor mutation data. Such graphs represent the path and the waiting times of alterations during tumor evolution. The probability of occurrence of each alteration in a path is the probability that the alteration occurs when all alterations prior to it have occurred. The waiting time between an alteration and the subsequent is modeled as a stochastic function of the conditional probability of the event given the occurrence of the previous one. TO-DAG performances have been evaluated both on synthetic data and on somatic non-silent mutations from prostate cancer and melanoma patients and then compared with those of current well-established approaches. TO-DAG shows high performance scores on synthetic data and recognizes mutations in gatekeeper tumor suppressor genes as trigger for several downstream mutational events in the human tumor data.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Melanoma genome sequencing reveals frequent PREX2 mutations

          Melanoma is notable for its metastatic propensity, lethality in the advanced setting, and association with ultraviolet (UV) exposure early in life 1 . To obtain a comprehensive genomic view of melanoma, we sequenced the genomes of 25 metastatic melanomas and matched germline DNA. A wide range of point mutation rates was observed: lowest in melanomas whose primaries arose on non-UV exposed hairless skin of the extremities (3 and 14 per Mb genome), intermediate in those originating from hair-bearing skin of the trunk (range = 5 to 55 per Mb), and highest in a patient with a documented history of chronic sun exposure (111 per Mb). Analysis of whole-genome sequence data identified PREX2 - a PTEN-interacting protein and negative regulator of PTEN in breast cancer 2 - as a significantly mutated gene with a mutation frequency of approximately 14% in an independent extension cohort of 107 human melanomas. PREX2 mutations are biologically relevant, as ectopic expression of mutant PREX2 accelerated tumor formation of immortalized human melanocytes in vivo. Thus, whole-genome sequencing of human melanoma tumors revealed genomic evidence of UV pathogenesis and discovered a new recurrently mutated gene in melanoma.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.

            Prostate cancer is the second most common cancer in men worldwide and causes over 250,000 deaths each year. Overtreatment of indolent disease also results in significant morbidity. Common genetic alterations in prostate cancer include losses of NKX3.1 (8p21) and PTEN (10q23), gains of AR (the androgen receptor gene) and fusion of ETS family transcription factor genes with androgen-responsive promoters. Recurrent somatic base-pair substitutions are believed to be less contributory in prostate tumorigenesis but have not been systematically analyzed in large cohorts. Here, we sequenced the exomes of 112 prostate tumor and normal tissue pairs. New recurrent mutations were identified in multiple genes, including MED12 and FOXA1. SPOP was the most frequently mutated gene, with mutations involving the SPOP substrate-binding cleft in 6-15% of tumors across multiple independent cohorts. Prostate cancers with mutant SPOP lacked ETS family gene rearrangements and showed a distinct pattern of genomic alterations. Thus, SPOP mutations may define a new molecular subtype of prostate cancer.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Lessons from the cancer genome.

              Systematic studies of the cancer genome have exploded in recent years. These studies have revealed scores of new cancer genes, including many in processes not previously known to be causal targets in cancer. The genes affect cell signaling, chromatin, and epigenomic regulation; RNA splicing; protein homeostasis; metabolism; and lineage maturation. Still, cancer genomics is in its infancy. Much work remains to complete the mutational catalog in primary tumors and across the natural history of cancer, to connect recurrent genomic alterations to altered pathways and acquired cellular vulnerabilities, and to use this information to guide the development and application of therapies. Copyright © 2013 Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Genet
                Front Genet
                Front. Genet.
                Frontiers in Genetics
                Frontiers Media S.A.
                1664-8021
                13 October 2015
                2015
                : 6
                : 309
                Affiliations
                [1] 1Laboratory of Computational Oncology, Centre for Integrative Biology, University of Trento Trento, Italy
                [2] 2Department of Physiology and Biophysics, Institute for Computational Biomedicine, Weill Medical College of Cornell University New York, NY, USA
                Author notes

                Edited by: Sven Bilke, National Cancer Institute/National Institutes of Health, USA

                Reviewed by: Karen Hubbard, The City College of New York, USA; Howard Donninger, University of Louisville, USA

                *Correspondence: Francesca Demichelis f.demichelis@ 123456unitn.it

                This article was submitted to Cancer Genetics, a section of the journal Frontiers in Genetics

                †Present Address: Paola Lecca, Association for Computing Machinery, New York, NY, USA

                Article
                10.3389/fgene.2015.00309
                4602157
                26528329
                28b36c91-c14e-4df8-9d80-dcde89a8fdae
                Copyright © 2015 Lecca, Casiraghi and Demichelis.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 26 July 2015
                : 24 September 2015
                Page count
                Figures: 10, Tables: 10, Equations: 7, References: 39, Pages: 17, Words: 10489
                Funding
                Funded by: US Department of Defense Synergy Awards
                Award ID: PC101020
                Funded by: National Cancer Institute 10.13039/100000054
                Award ID: 2R01CA125612
                Award ID: R01CA116337
                Categories
                Oncology
                Methods

                Genetics
                mutagenetic graphs,timed graphs,cumulative cancer progression models,graph inference,prostate cancer,melanoma

                Comments

                Comment on this article